AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$CYAB

Key facts: Cyabra, Inc. (CYAB) Wins FBI OSINT IDIQ; Pompeo Joins Board

Cyabra, Inc. (CYAB) secured a position on the FBI's Specialized OSINT Tools IDIQ, allowing task orders through 2031. Michael R. Pompeo joined the company's board as non-executive chairman. Cyabra is a Nasdaq-listed digital-risk intelligence firm.

Original reporting
tradingview.com
Published Oct 6, 2026, 7:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Key facts: Cyabra, Inc. (CYAB) Wins FBI OSINT IDIQ; Pompeo Joins Board — source image
Source · tradingview.com
Decision brief

The 30-second read

$CYABBullishMed
01

Why it matters

The FBI award provides a credible endorsement and a multi‑year revenue pipeline, potentially lifting the stock.

02

Market read

First disclosure of a federal contract to Cyabra, likely a catalyst for short‑term price appreciation.

03

What to watch

Execution risk and future task‑order competition could temper long‑term revenue upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Cyabra is a Nasdaq‑listed digital‑risk intelligence company focusing on open‑source intelligence (OSINT).

Company-level read

Ticker impact

$CYABBullishHigh confidence
Context

Cyabra, Inc. won a five‑year FBI OSINT tools IDIQ contract, securing a new revenue stream.

Expected impact

likely upward pressure as investors price in the new federal contract

Evidence & confidence

First‑report of a sizable government award to a Nasdaq‑listed cyber‑risk firm; no competing news dilutes the impact.

Market effects

Sector

May signal increased demand for OSINT and digital‑risk services across the cyber‑security sector.

Regional

U.S. federal contracts boost confidence in domestic cyber‑security providers.

Global

Limited to firms with U.S. government contracts; modest global ripple.

Counterpoint

What could challenge this read

If the contract is primarily a research‑only award with limited billings, the market reaction could be muted.

Key entities

  • company
    Cyabra, Inc.

    Nasdaq‑listed digital‑risk intelligence firm

  • government_agency
    Federal Bureau of Investigation

    U.S. law‑enforcement agency awarding the IDIQ contract

Read at source← All news

Related articles

AUG 13
$CYABMedAI 8/10

Cyabra Delivers Record Second Quarter Revenue with 39% Year-Over-Year Growth

Cyabra, Inc. (Nasdaq: CYAB) reported record Q2 2026 revenue of $1.9 million, up 39% year over year from $1.3 million, driven mainly by new customer wins and higher existing-customer revenue. Gross margin stayed about 84%. The company also cited a $500,000+ research institute agreement, new government and intelligence customers, and a $6.0 million private placement.

finanznachrichten.de6 min
JUL 9
$CYABMedAI 8/10

Cyabra Announces Pricing of $6.0 Million Private Placement Priced At a Premium to the Market Price with New and Existing Institutional Investors, Management, and Board Members

Cyabra, Inc. (Nasdaq: CYAB) priced a $6.0 million private placement to sell 13,818,770 shares plus Series A and Series B warrants at $0.435 per share. Series A warrants exercise at $0.50 and expire five years; Series B exercise at $0.45 and expire 12 months, both subject to stockholder approval. Preferred shares will convert to common or equivalents, pending approval.

manilatimes.net4 min
OCT 9
$LEVIMed

BNP Paribas Exane raises Levi Strauss price target to $35

BNP Paribas Exane raised its price target for Levi Strauss (LEVI) to $35, citing strong revenue growth and margins. The company reported Q3 revenue of $1.6B, up 4.3%, and EPS of $0.48, beating some estimates. Analysts note challenges in direct-to-consumer sales but see long-term growth potential. Other firms adjusted targets, ranging from $22 to $27.

investing.com2 min